tofacitinib,TLL-018
pfizer
['rova,(-approval),(-microvascular)', 'tofacitinib', 'tofa']
obviously lots of real world data at #eular2023 on jaki safety (cardiovascular &amp; cancer, see oral surveillance). real problem:
many still have shorter follow-up periods. cancer in particular takes time. it s great to see data now, but:
*longer follow-up needed* +++ 
Rheumatologist and clinical pharmacologist, world traveller pretences on the upswing, sometimes journal podcast host. All opinions my own